Human papillomavirus vaccines: Where do they fit in hiv-infected individuals?

Current HIV/AIDS Reports

Volumn 9, Issue 3, 2012, Pages 278-286

  Firnhaber, Cynthia ^a   Wilkin, Timothy ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

HIV; HPV; HPV cancer; HPV vaccine; Human papillomavirus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; DOUBLE STRANDED DNA; PLACEBO; PROTEIN E6; PROTEIN E7; VIRUS DNA; WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GENE EXPRESSION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MALE HOMOSEXUAL; MORBIDITY; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PENIS CANCER; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS CAPSID; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANUS TUMOR; CHILD; DEVELOPING COUNTRY; ECONOMICS; FEMALE; FEMALE GENITAL TRACT TUMOR; IMMUNOLOGY; MALE; MALE GENITAL TRACT TUMOR; OROPHARYNX TUMOR; REVIEW; UNITED STATES; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANUS NEOPLASMS; CHILD; DEVELOPING COUNTRIES; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84871701027     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0128-6     Document Type: Article

References (78)

1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65. (Pubitemid 34293391)
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9. (Pubitemid 29406813)
3. Firnhaber C, Zungu K, Levin S, et al. Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus -infected women in Johannesburg, South Africa. ACTA Cytological. 2009;53:10-7.
4. Yamada R, Sasagwa T, Kirumbi L, et al. Human Papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol. 2008;80:847-55. (Pubitemid 351500033)
5. Parham GP, Sahaarabuddhe W, Mwanahamuntu MH, et al. Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol. 2006;103(3):1017-22. (Pubitemid 44830069)
6. Cerqueira DM, Moraes DD, Camara GN, et al. High HPV genetic diversity in women infected with HIV-1 in Brazil. Arcb Virol. 2007;152(1):75-83. (Pubitemid 44974616)
7. Bollen L, Chuachoowong R, Kilmarx PH, et al. Human Papillomavirus (HPV) detection among human immunodeficiency virus - infected pregnant Thai women: implication for future HPV immunization. Sex Transm Dis. 2006;33(4):259-64.
8. Palefsky J. Human papillomavirus - related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52-6.
9. Lomanisa P, Smith T, Guidozzi F. Human Immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol. 2000;77:460-3. (Pubitemid 30368568)
10. Moodley M, Moodley J, Kleinschmidt I. Invasive cervical cancer and human immunodeficiency virus infection: a South African perspective. Int J Gynecol Cancer. 2001;11(3):194-7. (Pubitemid 32622665)
11. Harper D, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus -like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65. (Pubitemid 39488060)
12. Villa LL, Costa RL, Petta CA, et al. Prophylastic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: randomised double-blind placebo-controlled multicentres phase 11 efficacy trial. Lancet Oncol. 2005;6(5):271-8. (Pubitemid 40590263)
13. Brotherton JML, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria. Australia: an ecological study. Lancet. 2011;377:2085.
14. Shew M, Fortenberry D, Wanzhu T, et al. Association of condom use, sexual behaviours, and sexually transmitted infections with the duration of genital human papillomavirus among adolescent women. Arch Pediatr Adolesc Med. 2006;160:151-6. (Pubitemid 43213859)
15. IAC task Force. Human papillomavirus. Acta Cytol. 1998;42:50-8.
16. Munoz N, Bosch FX, Sanjose S, et al. Epidemiology classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27. (Pubitemid 36159887)
17. Louie SK, De Sanjose S, Mayaud P, et al. Epidemiology and prevention of human papillomavirus and cervical in sub-Saharan Africa: a comprehensive review. TropMed Int Health. 2009;14:1287- 302.
18. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24:S16-22.
19. Firnhaber C, Van Le H, Pettifor A, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Canc Causes Contr. 2010;21:433-43.
20. Lomalisa P, Smith T, Guidozzi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol. 2000;77(3):460-3. (Pubitemid 30368568)
21. Massad LS, Seaberg EC, Watts DH. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS. 2004;18:109-13. (Pubitemid 38402324)
22. Denny L, Boa R, Williamson A, et al. Human Papillomavirus infection and cervical disease in Human immunodeficiency virusinfected women. Obstel Gynaecol. 2008;111:1380-7.
23. Cardillo M, Hagan R, Abadi M. CD4 T-cell count, viral load and squamous intraepithelial lesions in women infected with the human immunodeficiency virus. Cancer (Cancer Cytopathol). 2001;93:111-4. (Pubitemid 32322165)
24. Smith JS, Lindsay L, Hoots B, et al. Human Papillomavirus type distribution in invasive cervical cancer and High grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32. (Pubitemid 46986496)
25. Clifford GM, Goncalves MAG, Franceschi S, et al. Human papillomavirus types among women infected with HIV: a met-analysis. AIDS. 2006;20:2337-44. (Pubitemid 44789536)
26. Sahasrabuddhe V, Mwanahamuntu MH, Vermund SH, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Canc. 2007;96:1480-3. (Pubitemid 46685795)
27. De Vuyst H, Gichangi P, Estambale B, et al. Human Papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer. 2008;122:244-6. (Pubitemid 350210001)
28. De Vuyst H, Ndirangu G, Moodley M, et al Prevalence of human papillomavirus in women with invasive cervical carcinoma by hIV status in Kenya and South Africa. Int J Cancer epub 2011
29. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37:1563-5 (Pubitemid 39658192)
30. Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among m en with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis. 2005;32:314-20. (Pubitemid 40578072)
31. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2008;48:491-9.
32. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-36. (Pubitemid 351717418)
33. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008;22:1203-11.
34. Silverberg M, Xu L, Chao C, et al. Immunodeficiency, HIV RNA levels, and risk of non-AIDS-defining cancers. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections [abstract 28]. February 16-19, 2010, San Francisco, California.
35. Silverberg M, Lau B, D'Souza, et al. Trends in cumulative incidence of cancer among HIV-infected patients in North America. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections [abstract 758]. February 16-19, 2010, San Francisco, California.
36. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120-30.
37. Munoz-Bongrand N, Poghosyan T, Zohar S, et al. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. Dis Colon Rectum. 2011;54(6):729-35.
38. Brown JE, Sunborg MJ, Kost E, et al. Vulvar cancer in human immunodefiency virus -seropositive premenopausal women: a case series and review of the literature. Journal of lower Genital Track Disease. 2005;9:7-10. (Pubitemid 40116721)
39. Elit L, Voruganti S, Simunovic M, et al. Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literature. Gynecol Oncol. 2005;98:151-4. (Pubitemid 40826433)
40. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-10.
41. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans 2007;90:1-670.
42. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-75. (Pubitemid 40270113)
43. Gillison M. Oropharyngeal cancer: a potential consequence of concomitant HPVand HIVinfection. Curr Opin Oncol. 2009;21:439-44.
44. Gillison M, Hagensee M, Marmor M, et al. High reproducibility of oral rinse and gargle (ORG) alone for detection of type-specific oral HPV infection. 26th International Papillomavirus Conference & Clinical and Public Health Workshops [abstract 671]. July 5, 2010, Montreal, Canada.
45. Auvert B, Marais D, Lissouba P, et al. High-risk pappilomavirus is associated with HIV acquisition among South African female sex workers. Infect Dis Obstet Gynecol. 2011;2011:1-9.
46. Mbulawa ZZA, Marias D Johnson L, et al. Influence of human immunodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples. J Gen Virol 2010,3023-3031
47. Mbulawa ZZA, Coetzee D, Marais DJ. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with Human immunodeficiency virus coinfection. J Infect Dis 2009;1514-24
48. Smith JS, Moses S, Hudgens MG, et al. Increase risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dise. 2010;201:1677-85.
49. Schim Van der Leff M., Nyitray AG, Giuliano A. HPV vaccination to prevent HIV infection: time for randomized controlled trials STD 2011 38:640-3
50. Chin-Hong PV, Husnik M, Cranston RD, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS. 2009;23(9):1135-42.
51. FUTURE II Study Group Quadrivalent Vaccine against human papillomavirus to prevent high-grade cervical lesions NEJM 2007 359 1915-1927
52. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 1928;2007:356.
53. Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med. 2007;356:1915- 27. (Pubitemid 46740302)
54. Giuliano AR, Palefsky JM, Goldstone S. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401-11. Erratum in: N Engl J Med. 2011 Apr 14;364(15):1481.
55. Palefsky JM, Giuliano AR, Goldstone S. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576- 85.
56. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. IMPAACT P1047 Protocol Team. J Acquir Immune Defic Syndr 2010;55:197-204. This study provides evidence that the HPV vaccine is safe and immunogenic in HIV-positive children. CD4 and HIV viral loads were not affected by the vaccine administration. Studies determining the clinical efficacy of the HPV vaccine are warranted in this population.
57. Wilkin T, Lee J, Lensing SY, et al. Safety and Immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1 infected men. JID 2010;202:1246-53. This study provides evidence that the HPV vaccine is safe and immunogenic in HIV-positive men. CD4 and HIV viral loads were not adversely affected. This study hints that the HPV vaccine might be effective in preventing anal dysplasia/cancer in an HR group. Studies determining the clinical efficacy of the HPV vaccine are warranted in this population.
58. Palefsky J,Wilkin TJ, Giuliano A. Lower level of titers in response to the HPV quadrivalent vaccine among men who have sex with men compared with heterosexual men. 26th International Papillomavirus Conference & Clinical and Public Health Workshops [abstract 670]. July 5, 2010, Montreal, Canada.
59. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-25 years. Br J Cancer. 2011;105:28-37.
60. Firnhaber C, Evans D, Friedman-Khalili R, et al. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botwana. J Clin Virol. 2011;2282:1-4.
61. Kojic EM, CespedesM, Umbleja T, et al. Baseline Seroprevalence of HPV Vaccine Types 6, 11, 16 and 18 in HIV-Infected Women Receiving the Quadrivalent Vaccine in the AIDS Clinical Trials Group Study A5240 abstract U 108 CROI 18 Boston 2011
62. Bonanni P, Boccalini S, Bechini A, et al. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of evidence. Vaccine. 2009;27:A46-53.
63. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effective of a human papillomavirus 16/18 vaccine. J Natl Canc Inst. 2004;96:604.
64. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16, 18 vaccinations in 72 Gavi-eligible countries. Vaccine. 2008;26:4080-93.
65. Sinanovic E, Moodley J, Barone MA, et al. The potential costeffectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2010;27(44):6196-202. Epub 2009 Aug 19. Erratum in: Vaccine. 2010 Aug 9;28(35):5755.
66. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):815-6.
67. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC et al. Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-53. (Pubitemid 47263157)
68. Joura E, Garland S, Paavone J. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401.
69. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891-8.
70. Wright Jr TC, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol. 1994;55(2):253-8. (Pubitemid 24366635)
71. Heard I, Potard V, Foulot H, et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr. 2005;39(4):412-8. (Pubitemid 41003785)
72. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis. 2007;11(2):90-7. (Pubitemid 46597702)
73. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103(18):1387-96. Epub 2011 Sep 6.
74. Kreimer AR, Schiffman M, Herrero R, et al Long-term risk of recurrent cervical HPV infection and precancer and cancer following excisional treatment. Int J Canc 2011 Aug 5. doi: 10.1002/ijc.26349.
75. Joura E, Hernanez-Avila M, Wheeler C, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11,16, and 18) L1 virus-like -particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693-702. (Pubitemid 46783792)
76. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC et al. CVT Vaccine Group. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011;12(9):862-70.
77. Paavonen J, Naud P, Salmeron J, et al. Efficacy of the human papillomavirus (HPV) - 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double blind randomised study in young women. Lancet. 2009;374:301-14.
78. Wheeler CM, Castellsaque X, Garland S, et al. Cross-protective efficacy of HPV 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4 year end of study analysis of the randomised, doubleblind PATRICIA trial. Lancet Oncol 2012;13:100-10. This analysis demonstrates that cross-protection both in persistent HPV infection and CIN2+ disease occurs at some level to 12 non-vaccine oncogenic types of HPV. This is crucial as HIV-infected women are at HR for multiple and diverse HR HPV infections.